Physician profile
Navin Victor
NPI 1972899268
$3,048.37
in general payments reported to CMS, 2019-2025
29 companies · $469 in 2025
The $469 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $124 · 2021: $672 · 2022: $574 · 2023: $809 · 2024: $402 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,562 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.55 |
| Education | $117.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $591.18 | 2021-2025 | Airsupra, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $540.57 | 2020-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.63 | 2021-2025 | Ofev, Jascayd, Spiriva Respimat |
| Amgen INC. | $236.04 | 2023-2025 | Tezspire, Tavneos |
| Actelion Pharmaceuticals US, INC. | $217.76 | 2020-2025 | Uptravi, Opsynvi |
| Mallinckrodt Hospital Products INC. | $137.92 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.28 | 2022-2025 | Cuvitru, Glassia |
| Ani Pharmaceuticals, INC. | $95.97 | 2022-2023 | Purified Cortrophin Gel |
| Janssen Pharmaceuticals, INC | $82.06 | 2021-2023 | Xarelto |
| Grifols USA, LLC | $68.89 | 2022-2023 | Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $66.46 | 2023-2024 | |
| Advanced Respiratory, INC | $61.48 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $59.86 | 2020-2021 | |
| Verona Pharma, INC. | $50.97 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $49.44 | 2023-2024 | Recarbrio, Zerbaxa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $47.91 | 2021-2022 | |
| Genzyme Corporation | $46.79 | 2022-2025 | |
| Mylan Specialty L.P. | $40.69 | 2024 | Yupelri |
| Paratek Pharmaceuticals, INC. | $39.26 | 2021-2022 | |
| Pulmonx Corporation | $34.72 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Sunovion Pharmaceuticals INC. | $30.24 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $29.78 | 2023 | Dupixent |
| Baxter Healthcare | $26.69 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Pharming Healthcare, INC. | $26.09 | 2022-2023 | Ruconest |
| Harmony Biosciences LLC | $22.84 | 2025 | |
| Nabriva Therapeutics, Plc | $20.72 | 2021 | |
| Inogen, INC. | $19.20 | 2021 | |
| Electromed, INC. | $16.12 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.81 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navin Victor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.